Marcelo Tatit Sapienza

Prof. Marcelo Tatit Sapienza

USP, São Paulo, Brazil
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
DFDaniela A. Ferraro
Daniela A. Ferraro
ABAnton S. Becker
Anton S. Becker
BKBenedikt Kranzbühler
Benedikt Kranzbühler
IMIliana Mebert
Iliana Mebert
ABAnka Baltensperger
Anka Baltensperger
IBIrene A. Burger
Irene A. Burger
Purpose: Ultrasound-guided biopsy (US biopsy) with 10–12 cores has a suboptimal sensitivity for clinically significant prostate cancer (sigPCa). If US biopsy is negative, magnetic resonance imaging (MRI)–guided biopsy is recommended, despite a low specificity for lesions with score 3–5 on Prostate Imaging Reporting and Data System (PIRADS). Screening and biopsy guidance using an imaging modality with high accuracy could reduce the number of unnecessary biopsies, reducing side effects. The aim of this study was to assess the performance of positron emission tomography/MRI with 68Ga-labeled prostate-specific membrane antigen (PSMA-PET/MRI) to detect and localize primary sigPCa (ISUP grade group 3 and/or cancer core length ≥ 6 mm) and guide biopsy. Methods: Prospective, open-label, single-center, non-randomized, diagnostic accuracy study including patients with suspected PCa by elevation of prostate-specific antigen (PSA) level and a suspicious lesion (PIRADS ≥3) on multiparametric MRI (mpMRI). Forty-two patients underwent PSMA-PET/MRI followed by both PSMA-PET/MRI-guided and section-based saturation template biopsy between May 2017 and February 2019. Primary outcome was the accuracy of PSMA-PET/MRI for biopsy guidance using section-based saturation template biopsy as the reference standard. Results: SigPCa was found in 62% of the patients. Patient-based sensitivity, specificity, negative and positive predictive value, and accuracy for sigPCa were 96%, 81%, 93%, 89%, and 90%, respectively. One patient had PSMA-negative sigPCa. Eight of nine false-positive lesions corresponded to cancer on prostatectomy and one in six false-negative lesions was negative on prostatectomy. Conclusion: PSMA-PET/MRI has a high accuracy for detecting sigPCa and is a promising tool to select patients with suspicion of PCa for biopsy. Trial registration: This trial was retrospectively registered under the name “Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men with Elevated PSA” (NCT03187990) on 06/15/2017 (https://clinicaltrials.gov/ct2/show/NCT03187990).

26 October 2010 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
BGBruno Gualano
Bruno Gualano
VPVitor de Salles Painelli
Vitor de Salles Painelli
Hamilton RoschelHamilton Roschel
Hamilton Roschel
RLRebeca Lugaresi
Rebeca Lugaresi
EDEgidio Dorea
Egidio Dorea
PJProf.Dr.Antonio Lancha Junior
Prof.Dr.Antonio Lancha Junior

19 September 2001 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MTMarcia G. Tavares
Marcia G. Tavares
MSMarcelo Tatit Sapienza
Marcelo Tatit Sapienza
NGNassif A. Galeb
Nassif A. Galeb
FBFrancisco A. Belfort
Francisco A. Belfort
RCRonaldo R. Costa
Ronaldo R. Costa
MMMarilia M. Marone
Marilia M. Marone

1 August 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
Hamilton RoschelHamilton Roschel
Hamilton Roschel
AHAna Paula Hayashi
Ana Paula Hayashi
AFAlan L. Fernandes
Alan L. Fernandes
JJJosé Claudio Jambassi-Filho
José Claudio Jambassi-Filho
VHVictoria Hevia-Larraín
Victoria Hevia-Larraín
BGBruno Gualano
Bruno Gualano

14 February 2019 in Diabetes
Verified
Journal Article
Closed access
PDF file
BHBruno Halpern
Bruno Halpern
MMMarcio C. Mancini
Marcio C. Mancini
CBClarissa Bueno
Clarissa Bueno
IBIsabella P. Barcelos
Isabella P. Barcelos
MMMaria Edna de Melo
Maria Edna de Melo
JNJosé Cipolla Neto
José Cipolla Neto
Melatonin, a pineal hormone synthesized at night, is critical for the synchronization of circadian and seasonal rhythms, being a key regulator of energy metabolism in many animal species. Although studies in humans are lacking, several reports, mainly on hibernating animals, demonstrated that melatonin supplementation and a short photoperiod increase brown adipose tissue (BAT) mass. The present proof-of-concept study is the first, to our knowledge, to evaluate BAT in patients with melatonin deficiency (radiotherapy or surgical removal of pineal gland) before and after daily melatonin (3 mg) replacement for 3 months. All four studied patients presented increased BAT volume and activity measured by positron emission tomography-MRI. We also found an improvement in total cholesterol and triglyceride blood levels without significant effects on body weight, liver fat, and HDL and LDL levels. Albeit not statistically significant, fasting insulin levels and HOMA of insulin resistance decreased in all four patients. The present results show that oral melatonin replacement increases BAT volume and activity and improves blood lipid levels in patients with melatonin deficiency, suggesting that melatonin is a possible BAT activator. Future studies are warranted because hypomelatoninemia is usually present in aging and appears as a result of light-at-night exposure and/or the use of β-blocker drugs.

12 January 2022 in Kidney International
Verified
Journal Article
Closed access
VSVerônica Torres Costa e Silva
Verônica Torres Costa e Silva
LGLuiz A. Gil
Luiz A. Gil
LILesley A. Inker
Lesley A. Inker
RCRenato A. Caires
Renato A. Caires
ECElerson Costalonga
Elerson Costalonga
EBEmmanuel A. Burdmann
Emmanuel A. Burdmann